Adocia announces an oral presentation at the 55th European Association for the Study of Diabetes EASD congress, being held September 16-20, 2019 in Barcelona, Spain.
This Abstract will cover its ADO09 (pramlintide insulin) product:
- Oral Presentation #109: ADO09, a co-formulation of the amylin-analog pramlintide and the A21G human insulin analog, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes
Presenting Author: Dr. Grégory Meiffren
Session: OP 19 Treating diabetes with peptides from the gut
Date and Time: Wednesday, September 18, 2019 2:30 PM – 4:00 PM CEST
Location: Joslin Hall